Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InSilico Medicine Cayman TopCo ( (HK:3696) ) has provided an announcement.
InSilico Medicine has entered a strategic drug development partnership with China Medical System Holdings to apply its AI-driven discovery platform across multiple programs targeting central nervous system and autoimmune diseases. The collaboration will pair Insilico’s AI and in-house R&D capabilities with CMS’s clinical development and commercialization expertise, with Insilico expected to receive up to several tens of millions of Hong Kong dollars in R&D funding for each of at least two co-developed programs, strengthening its position in AI-enabled therapeutics and expanding its pipeline in high-need therapeutic areas.
More about InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo is a Hong Kong–listed global biotechnology company that integrates artificial intelligence and automation to accelerate drug discovery and development. Its Pharma.AI platform underpins programs in fibrosis, oncology, immunology, pain, obesity and metabolic disorders, while also extending into adjacent areas such as advanced materials, agriculture, nutritional products and veterinary medicine.
Average Trading Volume: 4,627,580
Current Market Cap: HK$35.53B
For an in-depth examination of 3696 stock, go to TipRanks’ Overview page.